VectorY
3 employees
Biotech
Series A · $175.0M
Open positions (1)
Company details
Team Size3
IndustryBiotech
Funding
Total raised
$175.0M
Last stage
Series A
Investors
BioGeneration Ventures
Total raised
$175.0M
Last stage
Series A
Investors
Sander van Deventer
Physician-scientist with 25 years in drug development; played a critical role in developing the first commercial monoclonal antibody (Remicade) and first approved gene therapy in the West (Glybera); co-founder of uniQure and Forbion.
LinkedIn
Barbara Sanders
PhD in molecular virology (University of Amsterdam); over 10 years of experience in viral vector development; led development of the Ebola vaccine Zabdeno; inventor of eight patents.
LinkedInPavlina Konstantinova
Co-founder of VectorY Therapeutics, serving as Chief Scientific Officer.
No applications, no recruiter spam. Just the intro.
A few questions to make sure this role is the right shape for you. Two minutes.
I write the intro, send it to the founder, and handle the back-and-forth.
If they’re a yes, I book the chat. You show up — that’s the whole job-hunt.